Using Antibody-Drug Conjugates for Treatment of AML
Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.
Alexander E. Perl, MD, associate professor of medicine at the University of Pennsylvania, discusses the use of antibody-drug conjugates (ADC) in acute myeloid leukemia (AML). Gemtuzumab ozogamicin (Mylotarg) has already been approved for this patient population.
This agent was previously approved for relapsed disease, but withdrawn for single-agent use due to toxicity concerns.
Nonetheless, randomized data supported the use of this ADC in patients with AML. It is important to understand in which patients this treatment is most effective, which Perl notes as patients with relatively favorable chemotherapy-sensitive genotypes.
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
